Presentation to be Made on Tuesday, December 11, 2007 at 3:30PM/EST
EMERYVILLE, CALIF., December 4 /CNW/ - NovaBay Pharmaceuticals, Inc.
(AMEX & TSX: NBY, http://www.novabaypharma.com), a biopharmaceutical company
developing products for the treatment or prevention of a wide range of
bacterial and viral infections, will present at the New York Society of
Security Analysts' ("NYSSA") 11th Annual Biotech/Specialty Pharma Conference
held at the NYSSA's headquarters in New York City on Tuesday, December 11 at
3:30PM/EST. The live PowerPoint presentation with streaming video will be
webcast and archived for one year at:
(Due to its length, this URL may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one exists.)
Jack O'Reilly, NovaBay's SVP, Corporate Development and Chief Financial
Officer, will provide an overview of the company's clinical development
programs and the status of its licensing agreements with affiliates of Alcon,
Inc. (NYSE: ACL) and Kinetic Concepts, Inc. (NYSE: KCI). Mr. O'Reilly will also
highlight NovaBay's recently reported positive Phase I safety results for its
lead Aganocide compound, NVC-422, a novel non-antibiotic anti-infective that
has shown potent in vitro activity against major pathogens, including
methicillin-resistant Staphylococcus aureus (MRSA).
California based NovaBay recently closed an initial public offering (IPO)
of common stock on October 31, 2007, and is dually listed on the American
Stock Exchange and the Toronto Stock Exchange under the symbol "NBY."
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing innovative product candidates targeting the treatment or prevention
of a wide range of infections in hospital and non-hospital environments.
NovaBay has discovered and is developing a class of non-antibiotic
anti-infective compounds, which it has named Aganocide compounds, based upon
small molecules that are generated by white blood cells that defend the body
against invading pathogens. NovaBay believes that Aganocide compounds could
form a platform on which to create a variety of products to address differing
needs in the treatment and prevention of bacterial, fungal and viral
infections, including methicillin-resistant Staphylococcus aureus (MRSA).
NovaBay has entered into a licensing and research collaboration agreement with
an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear
and sinus and in contact lens solutions and a license agreement with an
affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase
product in woundcare applications.
NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay
Pharmaceuticals, Inc. All other trademarks and trade names are the property of
their respective owners.
For more information visit the company's website at
This release contains forward-looking statements, which are based upon
management's current expectations, assumptions, estimates, projections and
beliefs. These statements include, but are not limited to, statements
regarding the development and potential benefits of, and the market
opportunities for, NovaBay's product candidates. Forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause actual results or achievements to be materially different and adverse
from those expressed in or implied by the forward-looking statements. Factors
that might cause or contribute to such differences include, but are not
limited to, risks and uncertainties relating to difficulties or delays in
discovery, development, testing, regulatory approval, production and marketing
of the company's product candidates, unexpected adverse side effects or
inadequate therapeutic efficacy of the product candidates, the uncertainty of
patent protection for the company's intellectual property or trade secrets,
the company's ability to obtain additional financing as necessary and
unanticipated research and development and other costs. The forward-looking
statements in this release speak only as of this date, and NovaBay disclaims
any intent or obligation to revise or update publicly any forward-looking
statement except as required by law.
For further information:
For further information: The Investor Relations Group Investor
Relations: Adam Holdsworth / Rachel Colgate / Erica Ruderman 212-825-3210 or
Media Relations: Janet Vasquez / Susan Morgenbesser 212-825-3210